Higher AMH levels lower ovulation chances during induction with clomiphene and metformin in PCOS patients

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-05 16:45 GMT   |   Update On 2024-01-05 16:46 GMT
Advertisement

USA: A recent study published in Fertility and Sterility has shown reduced odds of ovulation with ovulation induction (OI) with clomiphene, metformin, and clomiphene+metformin with a higher Anti-Müllerian hormone (AMH) concentration in women with polycystic ovary syndrome (PCOS) and infertility.

"Higher baseline AMH concentrations were associated with a 10% reduction in the odds of ovulation per 1 ng/mL increase," the researchers reported. "Women with elevated baseline AMH (>8 ng/mL) had significantly lower ovulation rates in comparison."

Advertisement

Allison S Komorowski, Department of Obstetrics & Gynecology, Chicago, IL, USA, and colleagues described serum anti-Müllerian hormone concentrations in a large, well-phenotyped cohort of women with PCOS and evaluated whether AMH predicts successful ovulation induction in women treated with clomiphene and metformin.

For this purpose, the researchers performed a secondary analysis of a randomized controlled trial SUBJECTS: 333 women with anovulatory infertility attributed to PCOS who participated in the double-blind randomized trial entitled The Pregnancy in Polycystic Ovary Syndrome I (PPCOS I) study. These participants had serum samples from baseline laboratory testing available for further serum analysis.

The researchers assessed the association between baseline AMH concentration in each of the three treatment groups and ovulation rates, pregnancy rates and live birth rates.

The study revealed the following findings:

  • 322 individuals had a baseline AMH concentration available, of which the mean AMH was 11.7 ± 8.3 ng/mL with a range from 0.1 to 43.0 ng/mL.
  • With each unit (1 ng/mL) increase in baseline AMH, the odds of ovulation reduced by 10 per cent (OR 0.90); this effect did not differ by treatment group.
  • Women with a high baseline AMH concentration (>8 ng/mL) were significantly less likely to ovulate compared to those with a normal baseline AMH concentration (<4 ng/mL) (OR 0.23). This remained statistically significant when controlling for confounders, including body mass index, age, time in study, and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) score.
  • Ovulation occurred even at very high AMH concentrations; there was no maximum level noted at which no ovulation events occurred.
  • When controlling for confounders, baseline AMH concentration was not associated with pregnancy or live birth rates.

"These AMH values of well-phenotyped women with PCOS add to the literature and will aid in identifying AMH criteria for PCOS diagnosis," the researchers wrote.

"A higher AMH concentration was associated with reduced odds of ovulation with OI with clomiphene, metformin, and clomiphene+metformin in women with infertility and PCOS," they concluded.

Reference:

Komorowski AS, Hughes L, Sarkar P, Aaby DA, Kumar A, Kalra B, Legro RS, Boots CE. Anti-Müllerian Hormone Level Predicts Ovulation in Women with Polycystic Ovary Syndrome Treated with Clomiphene and Metformin. Fertil Steril. 2023 Dec 26:S0015-0282(23)02102-7. doi: 10.1016/j.fertnstert.2023.12.031. Epub ahead of print. PMID: 38154770.


Tags:    
Article Source : Fertility and Sterility

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News